Patent · US Active

Formulation containing TLR agonist and methods of use

US11344619B2 · kind B2 · utility

0Cited by
0References
17Claims
0Family size

Assignee

Inventor

Key dates

Filing dateMay 11, 2017
Grant dateMay 31, 2022
Priority date
Expiry dateAug 22, 2038

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Stable aqueous formulations of adjuvant comprising a TLR7/8 agonist or a TLR4 agonist with a helper lipid that are adsorbed to alum are provided. Compositions and methods of using the formulations for stimulating an immune response are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.